Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $8.33.
WHWK has been the subject of a number of analyst reports. Leerink Partners started coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They issued an “outperform” rating and a $9.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, September 2nd. B. Riley Financial assumed coverage on shares of Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a “buy” rating and a $10.00 target price on the stock. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Stifel Nicolaus assumed coverage on shares of Whitehawk Therapeutics in a report on Wednesday, September 30th. They set a “buy” rating and a $9.00 price target for the company.
Read Our Latest Stock Report on WHWK
Whitehawk Therapeutics Price Performance
Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. On average, equities analysts anticipate that Whitehawk Therapeutics will post -1.07 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in WHWK. Montanova Capital LLC increased its stake in Whitehawk Therapeutics by 16.2% during the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock worth $19,694,000 after acquiring an additional 600,000 shares during the last quarter. BlackRock Inc. purchased a new stake in Whitehawk Therapeutics in the second quarter valued at $8,807,000. ADAR1 Capital Management LLC purchased a new stake in Whitehawk Therapeutics in the second quarter valued at $6,144,000. Eversept Partners LP lifted its stake in shares of Whitehawk Therapeutics by 17.9% in the 1st quarter. Eversept Partners LP now owns 306,800 shares of the company’s stock valued at $1,058,000 after purchasing an additional 46,541 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Whitehawk Therapeutics in the 2nd quarter valued at $378,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.
Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.
Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited.
Featured Stories
- Five stocks we like better than Whitehawk Therapeutics
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
